GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (NAS:CMMB) » Definitions » Cash Conversion Cycle

CMMB (Chemomab Therapeutics) Cash Conversion Cycle : 0.00 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Chemomab Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2024 was .
Chemomab Therapeutics's Days Inventory for the three months ended in Sep. 2024 was .
Chemomab Therapeutics's Days Payable for the three months ended in Sep. 2024 was .
Therefore, Chemomab Therapeutics's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2024 was 0.00.


Chemomab Therapeutics Cash Conversion Cycle Historical Data

The historical data trend for Chemomab Therapeutics's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics Cash Conversion Cycle Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
- - - - -

Chemomab Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chemomab Therapeutics's Cash Conversion Cycle

For the Biotechnology subindustry, Chemomab Therapeutics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemomab Therapeutics's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Cash Conversion Cycle falls into.


';

Chemomab Therapeutics Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Chemomab Therapeutics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=+-
=0.00

Chemomab Therapeutics's Cash Conversion Cycle for the quarter that ended in Sep. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chemomab Therapeutics  (NAS:CMMB) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Chemomab Therapeutics Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Chemomab Therapeutics Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Executives
Orbimed Israel Biofund Gp Limited Partnership 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
George Adi Mor director, 10 percent owner, officer: Chief Executive Officer 15 KAFRISIN ST., TEL AVIV L3 6901658
Neil Harris Cohen director C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139
Matthew Bejosa Frankel officer: Chief Medical Officer 672 PROSPECT AVE., PRINCETON NJ 08540
Jill M. Quigley director TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Joel Michael Maryles director 5 ATZMON ST., HASHMONAIM L3 7312700
Donald Marvin officer: Executive VP, CFO & COO 2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104
Dale R Pfost director, officer: Chief Executive Officer ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Nissim Darvish director C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Peter Thiel 10 percent owner 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Sigal Fatal officer: Chief Financial Officer 16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716
Arnon Aharon officer: Chief Medical Officer 12 YAVNE ST., TEL AVIV L3 6579116
Alan Charles Moses director C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Stephen P Squinto director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Orbimed Israel Gp Ltd. 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629